Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 6/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 5/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.46 |
| ▸ | IKBKB | O14920 | 2/20 | 0.45 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.43 |
| ▸ | STK16 | O75716 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | ULK3 | Q6PHR2 | 1/20 | 0.43 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632155 | 0.92 | IKBKB (0.46) | JAK2BRD4FGFR1JAK3PTK2 | |
| SCHEMBL1633057 | 0.90 | EGFR (0.51) | JAK2BRD4FGFR4JAK3IKBKB | |
| SCHEMBL13498247 | 0.90 | IKBKB (0.44) | JAK2BRD4FGFR4AXLFGFR1 | |
| SCHEMBL1634505 | 0.90 | TBK1 (0.55) | JAK2JAK3PTK2IKBKBNUAK1 | |
| SCHEMBL1633715 | 0.86 | NTRK1 (0.42) | AXLPTK2IKBKBNUAK1STK16 | |
| SCHEMBL1632740 | 0.85 | CYP11B2 (0.42) | JAK2BRD4FGFR1JAK3IKBKB | |
| SCHEMBL1633031 | 0.83 | FGFR4 (0.47) | FGFR4AXLFGFR1PTK2IKBKB | |
| SCHEMBL1632623 | 0.82 | MAPK10 (0.53) | JAK2BRD4FGFR4AXLIKBKB | |
| SCHEMBL18376798 | 0.81 | JAK2 (0.55) | JAK2BRD4FGFR4AXLFGFR1 | |
| SCHEMBL1633192 | 0.81 | JAK2 (0.55) | JAK2BRD4FGFR4IKBKBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | JAK2 1352/4885BRD4 268/4885FGFR4 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.